Body Composition Research Moderate Evidence

Cagrilintide

Long-acting amylin analogue under investigation in combination with semaglutide (CagriSema). Amylin pathway complements GLP-1 mechanisms for potentially additive weight effects.

amylinweight losssatietygastric emptyingcombination

Ask AI About This Compare Compounds

Half-life

7 days

SKUs

Evidence

Moderate Evidence

📖 What Is This?

Cagrilintide is a long-acting synthetic analog of amylin, a hormone made in the pancreas that helps regulate appetite and how the body handles food after a meal. It is being studied in combination with semaglutide (a GLP-1 receptor agonist) in a program called CagriSema. Early results from that combination show strong effects on weight reduction, and phase 3 trials are underway.

🔬 What Are Researchers Studying It For?

Weight Management Research

Cagrilintide alone and in combination with semaglutide has been studied in phase 1 and phase 2 trials. The combination CagriSema showed weight losses averaging around 15-17% in a 32-week phase 2 trial, with ongoing phase 3 trials expected to provide more definitive data.

Amylin Pathway Research

Amylin is released alongside insulin after meals and contributes to satiety signaling through a different set of brain receptors than GLP-1. Cagrilintide was designed to capture this complementary satiety pathway in a once-weekly injectable form, something not previously available in a long-acting amylin analog.

Combination Metabolic Therapy

A major research interest in cagrilintide is its use alongside GLP-1 receptor agonists. Because amylin and GLP-1 signal through different pathways, combining them may produce additive satiety effects greater than either alone. The CagriSema combination is the lead development program.

📊 What Does The Research Suggest?

Phase 2 CagriSema trial showed approximately 15-17% weight reduction at 32 weeks.
Cagrilintide alone showed dose-dependent weight reduction in early phase trials.
The amylin pathway appears to complement GLP-1 effects on satiety through distinct brain receptors.
Phase 3 trials (REDEFINE program) are ongoing and results are expected in the next few years.

⚠️ What Should You Know Before Going Deeper?

Cagrilintide is not yet approved for any use. The most promising data come from the combination with semaglutide, not from cagrilintide alone. Phase 3 results are pending and could differ from earlier phase data. Nausea and GI side effects have been reported in trials. Long-term safety data are not yet available.

⚙️ How It Works In The Body

When you eat, your pancreas releases not just insulin but also a hormone called amylin. Amylin sends signals to the brain — particularly to areas that regulate fullness — telling you to stop eating, slow down how fast food moves out of your stomach, and reduce appetite for the next meal. Cagrilintide is a modified version of amylin that has been engineered to work for an entire week after a single injection. By keeping amylin-like signals active continuously, it adds a sustained appetite-reducing effect that is different from the GLP-1 pathway. When you combine cagrilintide with a GLP-1 agonist, you are hitting both satiety pathways at once, which researchers believe explains the stronger weight reduction seen in the combination trials.

🛡️ Research Safety Observations

Cagrilintide is investigational and not FDA-approved. In trials it has shown a GI side effect profile similar to amylin and GLP-1 class compounds, with nausea being most common during dose escalation. No serious safety signals beyond the class-related GI effects have been flagged in phase 2 data. Phase 3 safety data will be necessary before any approval decision.

📋 Research Snapshot

Moderate Evidence

This compound has been studied in Phase 1 or Phase 2 human trials. Evidence is encouraging but more large-scale trials are needed.

Published Research Ranges

0.3–4.5mg weekly in REDEFINE trials

Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.

📄 Research Sources

Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.

Amylin Receptor Agonism and the Satiety Signal: Review of Cagrilintide Mechanism

Journal of Clinical Endocrinology & Metabolism • 2022 • DOI: 10.1210/clinem/dgac289

Cagrilintide

Want More Detailed Research?